BFRI
Biofrontera Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.10
P/S
0.28
EV/EBITDA
-1.09
DCF Value
$-36.18
FCF Yield
-115.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.8%
Operating Margin
-27.2%
Net Margin
-25.3%
ROE
-1139.0%
ROA
-36.9%
ROIC
-66.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $17.1M | $5.6M | $0.48 |
| FY 2025 | $41.7M | $-10.5M | $-0.90 |
| Q3 2025 | $7.0M | $-6.6M | $-0.62 |
| Q2 2025 | $9.0M | $-5.3M | $-0.57 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.64
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.